Chimerix Leadership to Share Insights at Precision Medicine Forum

Author: Caleb Price Updated: 01-29-2025 04:25 PM

Chimerix to Showcase Innovation at Precision Medicine Symposium

Chimerix, a prominent biopharmaceutical company dedicated to creating life-changing medicines, has announced an exciting opportunity for industry engagement. Mike Andriole, the Chief Executive Officer, along with Tom Riga, the Chief Operating and Commercial Officer, will participate in a fireside chat at the upcoming JonesTrading Virtual Precision Medicine Symposium. This event is scheduled for Monday, February 3, 2025, at 11:00 a.m. ET.

Insights into the Future of Medicine

The futures of healthcare and biopharmaceuticals are increasingly intertwined. During the symposium, Chimerix's executives will share insights into their pioneering work aimed at improving patient outcomes in the face of life-threatening conditions. This chat will feature critical discussions surrounding their innovative research and development strategies, particularly how they align with the modern landscape of precision medicine.

Exploring Advanced Development Programs

Chimerix's standout development program, dordaviprone, is specifically targeted at H3 K27M-mutant glioma. Glioma is a challenging and aggressive form of brain cancer that impacts many lives. The development team is making strides, conducting Phase 1 dose escalation studies of another promising therapy, ONC206. This study focuses on safety and pharmacokinetic (PK) data, crucial for understanding how the body processes this innovative treatment.

Staying Connected with Investors

Participants interested in the symposium can tune in via an audio webcast that will be made available on the Investor Relations section of Chimerix's official website. This archived session will remain accessible for about 90 days, allowing for broader accessibility to investors and stakeholders who want to stay informed about Chimerix's latest advancements and strategic directions.

About the Company

At its core, Chimerix is guided by a robust mission: to develop medicines that significantly extend and improve the lives of patients battling severe diseases. The commitment to this mission drives their research initiatives, leading to advancements that could offer new hope to patients worldwide.

Contact Information for Interested Parties

For those looking to reach out for more information regarding this event or Chimerix's ongoing projects, the company is open for communication. Will O’Connor from Stern Investor Relations is the designated investor contact, and he can be reached through email. Additionally, media inquiries can be directed to Dana Davis at Steelwire, ensuring that all aspects of communication are well-handled.

Frequently Asked Questions

What is the focus of Chimerix's participation in the symposium?

Chimerix will highlight its innovative approaches in the development of therapies for deadly diseases during the chat.

Who are the key speakers at the fireside chat?

Mike Andriole, the CEO, and Tom Riga, the Chief Operating and Commercial Officer, will lead the discussion.

What topics will be discussed regarding drug development?

The discussion will primarily focus on dordaviprone and ONC206, including the latest findings from their research efforts.

How can one access the symposium?

Attendees can watch the session via an audio webcast on Chimerix’s Investor Relations website.

Is there a way to contact Chimerix for further inquiries?

Yes, Will O’Connor and Dana Davis can be contacted for investor and media inquiries respectively.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.